Cargando…
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
BACKGROUND: Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET). METHODS: This is a pooled analysis of two multicentre, randomised non-comparative phase 2 clinical trials evaluating neoadjuvant anastrozole an...
Autores principales: | Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, Quenel-Tueux, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078275/ https://www.ncbi.nlm.nih.gov/pubmed/32001832 http://dx.doi.org/10.1038/s41416-020-0733-x |
Ejemplares similares
-
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
por: Quenel-Tueux, Nathalie, et al.
Publicado: (2015) -
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018) -
Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer
por: Bellera, Carine A, et al.
Publicado: (2010) -
Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer centre
por: Linck, Pierre-Antoine, et al.
Publicado: (2021) -
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)